TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

Clinical trial NCT05948813 · RECRUITING

Trial details

NCT number: NCT05948813
Sponsor: TYK Medicines, Inc
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

NSCLC EGFR Activating Mutation Brain Metastases

Start date: 2023-08-17
Primary completion: 2025-06-30
Enrollment: 420

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.